{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:10:50Z","timestamp":1793250650332,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-026-03267-0","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T05:14:27Z","timestamp":1783142067000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Synergistic SGLT2 and GLP-1R targeting alleviates systemic inflammation-induced and M1 monocyte-driven endothelial dysfunction in coronary artery disease"],"prefix":"10.1186","volume":"25","author":[{"given":"Ali","family":"Mroueh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walaa","family":"Fakih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Kerth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinnosuke","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaimae","family":"Aboueddahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dal-Seong","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midam","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Nicolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Fass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonin","family":"Trimaille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Granier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"Amissi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Pompach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Ho","family":"Oak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Jesel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"G\u00f6rlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7295-3041","authenticated-orcid":false,"given":"Olivier","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9997-9287","authenticated-orcid":false,"given":"Val\u00e9rie","family":"Schini-Kerth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"key":"3267_CR1","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/nature01323","volume":"420","author":"P Libby","year":"2002","unstructured":"Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868\u201374. https:\/\/doi.org\/10.1038\/nature01323.","journal-title":"Nature"},{"key":"3267_CR2","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1707914.","journal-title":"N Engl J Med"},{"key":"3267_CR3","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1093\/eurheartj\/ehw024","volume":"37","author":"PM Ridker","year":"2016","unstructured":"Ridker PM. Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. Eur Heart J. 2016;37:1720\u20132. https:\/\/doi.org\/10.1093\/eurheartj\/ehw024.","journal-title":"Eur Heart J"},{"key":"3267_CR4","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMra043430","volume":"352","author":"GK Hansson","year":"2005","unstructured":"Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685\u201395. https:\/\/doi.org\/10.1056\/NEJMra043430.","journal-title":"N Engl J Med"},{"key":"3267_CR5","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/nm.2538","volume":"17","author":"C Weber","year":"2011","unstructured":"Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011;17:1410\u201322. https:\/\/doi.org\/10.1038\/nm.2538.","journal-title":"Nat Med"},{"issue":"6284","key":"3267_CR6","doi-asserted-by":"publisher","first-page":"aaf1098","DOI":"10.1126\/science.aaf1098","volume":"352","author":"MG Netea","year":"2016","unstructured":"Netea MG, Joosten LA, Latz E, Mills KH, Natoli G, Stunnenberg HG, et al. Trained immunity: a program of innate immune memory in health and disease. Science. 2016;352(6284):aaf1098. https:\/\/doi.org\/10.1126\/science.aaf1098.","journal-title":"Science"},{"key":"3267_CR7","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/eurheartj\/ehr304","volume":"33","author":"U F\u00f6rstermann","year":"2012","unstructured":"F\u00f6rstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J. 2012;33:829\u201337. https:\/\/doi.org\/10.1093\/eurheartj\/ehr304.","journal-title":"Eur Heart J"},{"key":"3267_CR8","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1161\/CIRCRESAHA.115.306301","volume":"118","author":"MA Gimbrone","year":"2016","unstructured":"Gimbrone MA, Garc\u00eda-Carde\u00f1a G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res. 2016;118:620\u201336. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.306301.","journal-title":"Circ Res"},{"key":"3267_CR9","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nri3520","volume":"13","author":"KJ Moore","year":"2013","unstructured":"Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol. 2013;13:709\u201321. https:\/\/doi.org\/10.1038\/nri3520.","journal-title":"Nat Rev Immunol"},{"key":"3267_CR10","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1504720.","journal-title":"N Engl J Med"},{"key":"3267_CR11","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827.","journal-title":"N Engl J Med"},{"key":"3267_CR12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3.","journal-title":"Lancet"},{"key":"3267_CR13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1161\/CIRCULATIONAHA.117.029352","volume":"137","author":"S Verma","year":"2018","unstructured":"Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit. Circulation. 2018;137:115\u20137. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.029352.","journal-title":"Circulation"},{"key":"3267_CR14","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1161\/CIRCRESAHA.114.301958","volume":"114","author":"JR Ussher","year":"2014","unstructured":"Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res. 2014;114:1788\u2013803. https:\/\/doi.org\/10.1161\/CIRCRESAHA.114.301958.","journal-title":"Circ Res"},{"issue":"1","key":"3267_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/JOE-24-0046","volume":"263","author":"N Mullur","year":"2024","unstructured":"Mullur N, Morissette A, Morrow NM, Mulvihill EE. GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms. J Endocrinol. 2024;263(1):1\u201314.","journal-title":"J Endocrinol"},{"key":"3267_CR16","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","volume":"61","author":"S Verma","year":"2018","unstructured":"Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61:2108\u201317. https:\/\/doi.org\/10.1007\/s00125-018-4670-7.","journal-title":"Diabetologia"},{"key":"3267_CR17","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41569-022-00824-4","volume":"20","author":"M Packer","year":"2023","unstructured":"Packer M. SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism. Nat Rev Cardiol. 2023;20:443\u201362. https:\/\/doi.org\/10.1038\/s41569-022-00824-4.","journal-title":"Nat Rev Cardiol"},{"key":"3267_CR18","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1097\/MOL.0b013e32830f4a06","volume":"19","author":"DO Haskard","year":"2008","unstructured":"Haskard DO, Boyle JJ, Mason JC. The role of complement in atherosclerosis. Curr Opin Lipidol. 2008;19:478\u201382. https:\/\/doi.org\/10.1097\/MOL.0b013e32830f4a06.","journal-title":"Curr Opin Lipidol"},{"issue":"13","key":"3267_CR19","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.3390\/nu15132878","volume":"15","author":"L Tan","year":"2023","unstructured":"Tan L, Lu X, Danser AHJ, Verdonk K. The role of chemerin in metabolic and cardiovascular disease: a literature review of its physiology and pathology from a nutritional perspective. Nutrients. 2023;15(13):2878. https:\/\/doi.org\/10.3390\/nu15132878.","journal-title":"Nutrients"},{"key":"3267_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1161\/01.ATV.0000150649.39934.13","volume":"25","author":"NR Madamanchi","year":"2005","unstructured":"Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol. 2005;25:29\u201338. https:\/\/doi.org\/10.1161\/01.ATV.0000150649.39934.13.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3267_CR21","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1161\/CIRCRESAHA.117.312465","volume":"122","author":"J Leentjens","year":"2018","unstructured":"Leentjens J, Bekkering S, Joosten LAB, Netea MG, Burgner DP, Riksen NP. Trained innate immunity as a novel mechanism linking infection and the development of atherosclerosis. Circ Res. 2018;122:664\u20139. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.312465.","journal-title":"Circ Res"},{"key":"3267_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/cr.2010.178","volume":"21","author":"MJ Morgan","year":"2011","unstructured":"Morgan MJ, Liu ZG. Crosstalk of reactive oxygen species and NF-\u03baB signaling. Cell Res. 2011;21:103\u201315. https:\/\/doi.org\/10.1038\/cr.2010.178.","journal-title":"Cell Res"},{"key":"3267_CR23","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/nri2725","volume":"10","author":"J Tschopp","year":"2010","unstructured":"Tschopp J, Schroder K. NLRP3 inflammasome activation. Nat Rev Immunol. 2010;10:210\u20135. https:\/\/doi.org\/10.1038\/nri2725.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"3267_CR24","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/cvr\/cvae257","volume":"121","author":"A Mroueh","year":"2025","unstructured":"Mroueh A, Algara-Suarez P, Fakih W, Gong DS, Matsushita K, Park SH, et al. SGLT2 expression in human vasculature and heart correlates with low-grade inflammation and causes eNOS-NO\/ROS imbalance. Cardiovasc Res. 2025;121(4):643\u201357. https:\/\/doi.org\/10.1093\/cvr\/cvae257.","journal-title":"Cardiovasc Res"},{"issue":"7","key":"3267_CR25","doi-asserted-by":"publisher","first-page":"101587","DOI":"10.1016\/j.jacbts.2026.101587","volume":"11","author":"W Fakih","year":"2026","unstructured":"Fakih W, Mroueh A, Kikuchi S, Marzak H, Amissi S, Gong DS, et al. Synergistic effects of SGLT2 inhibitors and GLP1R agonists on inflammation-associated oxidative stress in atrial fibrillation. JACC Basic Trans Science. 2026;11(7):101587. https:\/\/doi.org\/10.1016\/j.jacbts.2026.101587","journal-title":"JACC Basic Trans Science."},{"issue":"1","key":"3267_CR26","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jtha.2023.09.022","volume":"22","author":"A Mroueh","year":"2024","unstructured":"Mroueh A, Fakih W, Carmona A, Trimaille A, Matsushita K, Marchandot B, et al. COVID-19 promotes endothelial dysfunction and thrombogenicity: role of proinflammatory cytokines\/SGLT2 prooxidant pathway. J Thromb Haemost. 2024;22(1):286\u201399. https:\/\/doi.org\/10.1016\/j.jtha.2023.09.022.","journal-title":"J Thromb Haemost"},{"issue":"10","key":"3267_CR27","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/cvr\/cvae101","volume":"120","author":"W Fakih","year":"2024","unstructured":"Fakih W, Mroueh A, Gong DS, Kikuchi S, Pieper MP, Kindo M, et al. Activated factor Xa stimulates atrial endothelial cells and tissues to promote remodelling responses through AT1R\/NADPH oxidases\/SGLT1\/2. Cardiovasc Res. 2024;120(10):1138\u201354. https:\/\/doi.org\/10.1093\/cvr\/cvae101.","journal-title":"Cardiovasc Res"},{"issue":"146","key":"3267_CR28","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","volume":"13","author":"N Marx","year":"2022","unstructured":"Marx N, Husain M, Lehrke M, Verma S, Sattar N. GLP-1 Receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation. 2022;13(146):1882\u201394. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.059595.","journal-title":"Circulation"},{"key":"3267_CR29","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nri3793","volume":"15","author":"AR Tall","year":"2015","unstructured":"Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol. 2015;15:104\u201316. https:\/\/doi.org\/10.1038\/nri3793.","journal-title":"Nat Rev Immunol"},{"key":"3267_CR30","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.cell.2011.04.005","volume":"145","author":"KJ Moore","year":"2011","unstructured":"Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011;145:341\u201355. https:\/\/doi.org\/10.1016\/j.cell.2011.04.005.","journal-title":"Cell"},{"key":"3267_CR31","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.3389\/fimmu.2018.01930","volume":"9","author":"P Ruytinx","year":"2018","unstructured":"Ruytinx P, Proost P, Van Damme J, Struyf S. Chemokine-induced macrophage polarization in inflammatory conditions. Front Immunol. 2018;9:1930. https:\/\/doi.org\/10.3389\/fimmu.2018.01930.","journal-title":"Front Immunol"},{"key":"3267_CR32","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","volume":"41","author":"PJ Murray","year":"2014","unstructured":"Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. Macrophage activation guidelines. Immunity. 2014;41:14\u201320. https:\/\/doi.org\/10.1016\/j.immuni.2014.06.008.","journal-title":"Immunity"},{"key":"3267_CR33","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1161\/CIRCRESAHA.115.306256","volume":"118","author":"I Tabas","year":"2016","unstructured":"Tabas I, Bornfeldt KE. Macrophage phenotype in atherosclerosis. Circ Res. 2016;118:653\u201367. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.306256.","journal-title":"Circ Res"},{"key":"3267_CR34","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1161\/CIRCRESAHA.122.320877","volume":"131","author":"J Kamtchum-Tatuene","year":"2022","unstructured":"Kamtchum-Tatuene J, Saba L, Heldner MR, Poorthuis MHF, de Borst GJ, Rundek T, et al. Interleukin-6 predicts carotid plaque severity, vulnerability, and progression. Circ Res. 2022;131:e22\u201333. https:\/\/doi.org\/10.1161\/CIRCRESAHA.122.320877.","journal-title":"Circ Res"},{"key":"3267_CR35","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41591-025-04090-y","volume":"32","author":"R Sriranjan-Rothwell","year":"2026","unstructured":"Sriranjan-Rothwell R, Heffernan AJ, Baron JH, Channon KM, Choudhury RP, Kharbanda RK, et al. Low-dose IL-2 reduces arterial inflammation. Nat Med. 2026;32:412\u201325.","journal-title":"Nat Med"},{"key":"3267_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-026-01256-0","author":"I Fern\u00e1ndez-Ruiz","year":"2026","unstructured":"Fern\u00e1ndez-Ruiz I. Low-dose IL-2 therapy reduces arterial inflammation in acute coronary syndromes. Nat Rev Cardiol. 2026. https:\/\/doi.org\/10.1038\/s41569-026-01256-0.","journal-title":"Nat Rev Cardiol"},{"key":"3267_CR37","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","volume":"381","author":"JC Tardif","year":"2019","unstructured":"Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381:2497\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa1912388.","journal-title":"N Engl J Med"},{"key":"3267_CR38","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","volume":"383","author":"SM Nidorf","year":"2020","unstructured":"Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383:1838\u201347. https:\/\/doi.org\/10.1056\/NEJMoa2021372.","journal-title":"N Engl J Med"},{"key":"3267_CR39","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s00011-023-01718-y","volume":"72","author":"NB Amaral","year":"2023","unstructured":"Amaral NB, Rodrigues TS, Giannini MC, Lopes MI, Bonjorno LP, Menezes P, et al. Colchicine reduces the activation of NLRP3 inflammasome in COVID-19 patients. Inflamm Res. 2023;72:895\u20139. https:\/\/doi.org\/10.1007\/s00011-023-01718-y.","journal-title":"Inflamm Res"},{"key":"3267_CR40","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1111\/dom.15185","volume":"25","author":"DR Riley","year":"2023","unstructured":"Riley DR, Essa H, Austin P, Preston F, Kargbo I, Ibarburu GH, et al. All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes. Diabetes Obes Metab. 2023;25:2897\u2013909. https:\/\/doi.org\/10.1111\/dom.15185.","journal-title":"Diabetes Obes Metab"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-026-03267-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03267-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03267-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:18:48Z","timestamp":1790554728000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12933-026-03267-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3267"],"URL":"https:\/\/doi.org\/10.1186\/s12933-026-03267-0","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"13 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not Applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"OM declared grants from AstraZeneca, Medtronic and Boehringer Ingelheim and VSK. from Boehringer Ingelheim, Schwabe, and Servier. DSG and MHO were supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (IRIS RS-2025\u201325436621). The other authors have nothing to disclose. The authors received no financial support for the research, authorship, and publication of this article.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"292"}}